Now showing items 1-3 of 3

    • Group 5 drugs for multidrug-resistant tuberculosis: Individual patient data meta-analysis 

      Greg J. Fox; Andrea Benedetti; Helen Cox; Won Jung Koh; Piret Viiklepp; Shama Ahuja; Geoffrey Pasvol; Dick Menzies; Dick Menzies; S. Ahuja; D. Ashkin; M. Avendaño; R. Banerjee; M. Bauer; M. G. Hollm-Delgado; M. Pai; L. Shah; J. N. Bayona; M. Becerra; M. Becerra; M. Burgos; R. Centis; L. D'Ambrosio; G. B. Migliori; E. D. Chan; C. Y. Chiang; W. C.M. De Lange; R. Van Altena; T. S. Van Der Werf; K. De Riemer; N. H. Dung; D. Enarson; D. Falzon; R. M. Granich; K. Flanagan; J. Flood; N. Gandhi; L. Garcia-Garcia; T. H. Holtz; M. Iseman; M. J. Strand; L. G. Jarlsberg; S. Royce; S. Keshavjee; H. R. Kim; C. D. Mitnick; J. Lancaster; M. Van Der Walt; C. Lange; V. Leimane; V. Riekstina; C. C. Leung; J. Li; M. Narita; P. O'Riordan; D. Palmero; S. K. Park; J. Pena; C. Pérez-Guzmán; A. Ponce-De-Leon; J. Sifuentes-Osornio; M. I.D. Quelapio; T. E. Tupasi; J. Robert; H. S. Schaaf; K. J. Seung; S. S. Shin; T. S. Shim; Y. Shiraishi; G. Sotgiu; P. Tabarsi; M. H. Vargas; J. Westenhouse; W. W. Yew; J. J. Yim (2017-01-01)
      Copyright © ERS 2017. The role of so-called "group 5" second-line drugs as a part of antibiotic therapy for multidrug-resistant tuberculosis (MDR-TB) is widely debated. We performed an individual patient data meta-analysis ...
    • Group 5 drugs for multidrug-resistant tuberculosis: Individual patient data meta-analysis 

      Greg J. Fox; Andrea Benedetti; Helen Cox; Won Jung Koh; Piret Viiklepp; Shama Ahuja; Geoffrey Pasvol; Dick Menzies; Dick Menzies; S. Ahuja; D. Ashkin; M. Avendaño; R. Banerjee; M. Bauer; M. G. Hollm-Delgado; M. Pai; L. Shah; J. N. Bayona; M. Becerra; M. Becerra; M. Burgos; R. Centis; L. D'Ambrosio; G. B. Migliori; E. D. Chan; C. Y. Chiang; W. C.M. De Lange; R. Van Altena; T. S. Van Der Werf; K. De Riemer; N. H. Dung; D. Enarson; D. Falzon; R. M. Granich; K. Flanagan; J. Flood; N. Gandhi; L. Garcia-Garcia; T. H. Holtz; M. Iseman; M. J. Strand; L. G. Jarlsberg; S. Royce; S. Keshavjee; H. R. Kim; C. D. Mitnick; J. Lancaster; M. Van Der Walt; C. Lange; V. Leimane; V. Riekstina; C. C. Leung; J. Li; M. Narita; P. O'Riordan; D. Palmero; S. K. Park; J. Pena; C. Pérez-Guzmán; A. Ponce-De-Leon; J. Sifuentes-Osornio; M. I.D. Quelapio; T. E. Tupasi; J. Robert; H. S. Schaaf; K. J. Seung; S. S. Shin; T. S. Shim; Y. Shiraishi; G. Sotgiu; P. Tabarsi; M. H. Vargas; J. Westenhouse; W. W. Yew; J. J. Yim (2017-01-01)
      Copyright © ERS 2017. The role of so-called "group 5" second-line drugs as a part of antibiotic therapy for multidrug-resistant tuberculosis (MDR-TB) is widely debated. We performed an individual patient data meta-analysis ...
    • Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients 

      Shama D. Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N. Bayona; Mercedes C. Becerra; Mercedes C. Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D. Chan; Chen Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L. Garcia-Garcia; Neel Gandhi; Reuben M. Granich; Maria G. Hollm-Delgado; Timothy H. Holtz; Michael D. Iseman; Leah G. Jarlsberg; Salmaan Keshavjee; Hye Ryoun Kim; Won Jung Koh; Joey Lancaster; Christophe Lange; Wiel C.M. de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B. Migliori; Sergey P. Mishustin; Carole D. Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I.D. Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H. Simon Schaaf; Kwonjune J. Seung; Lena Shah; Tae Sun Shim; Sonya S. Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J. Strand; Payam Tabarsi; Thelma E. Tupasi; Robert van Altena; Martie van der Walt; Tjip S. van der Werf; Mario H. Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae Joon Yim (2012-08-01)
      Background: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of ...